Short answer
Revolution Medicines Inc (RVMD) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for quarter ended September 30, 2026.
Revolution Medicines Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Full results and management commentary available in Exhibit 99.1
- Investor focus: cash runway, RAS oncology pipeline progress and development spending in the accompanying release
Item EX-99.1 · Exhibit EX-99.1
- RASONQUE U.S. launch generated $197.6 million revenue in roughly five weeks, establishing Revolution Medicines as a commercial-stage oncology company
- More than 5,000 patients received RASONQUE, while payer claims covered over 90% of U.S. PDAC lives, supporting early access momentum
- Cash and marketable securities reached $3.7 billion, excluding $250 million received in October from Royalty Pharma debt financing
- R&D rose to $417.1 million and SG&A to $153.3 million, reflecting intensified pipeline investment and commercialization costs
- Net loss widened to $407.5 million, while full-year 2026 operating expense guidance remained $2.1 billion to $2.2 billion
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Revolution Medicines Inc 8-K filings
Get the next RVMD 8-K as it lands
Follow RVMD for push alerts, or ask the research agent what this filing means.